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Abstract
Introduction The invasive, mesenchymal phenotype of
CD44posCD24neg  breast cancer cells has made them a
promising target for eliminating the metastatic capacity of
primary tumors. It has been previously demonstrated that
CD44neg/lowCD24pos breast cancer cells lack the ability to give
rise to their invasive CD44posCD24neg counterpart. Here we
demonstrate that noninvasive, epithelial-like CD44posCD24pos
cells readily give rise to invasive, mesenchymal
CD44posCD24neg  progeny  in vivo and  in vitro. This
interconversion was found to be dependent upon Activin/Nodal
signaling.
Methods Breast cancer cell lines were sorted into
CD44posCD24pos and CD44posCD24neg populations to evaluate
their progeny for the expression of CD44, CD24, and markers of
a mesenchymal phenotype. The populations, separated by
fluorescence activated cell sorting (FACS) were injected into
immunocompromised mice to evaluate their tumorigenicity and
invasiveness of the resulting xenografts.
Results CD24 expression was dynamically regulated in vitro in
all evaluated breast cancer cell lines. Furthermore, a single
noninvasive, epithelial-like CD44posCD24pos cell had the ability
to give rise to invasive, mesenchymal CD44posCD24neg
progeny. Importantly, this interconversion occurred in vivo as
CD44posCD24pos  cells gave rise to xenografts with locally
invasive borders as seen in xenografts initiated with
CD44posCD24neg cells. Lastly, the ability of CD44posCD24pos
cells to give rise to mesenchymal progeny, and vice versa, was
blocked upon ablation of Activin/Nodal signaling.
Conclusions Our data demonstrate that the invasive,
mesenchymal CD44posCD24neg phenotype is under dynamic
control in breast cancer cell lines both in vitro and  in vivo.
Furthermore, our observations suggest that therapies targeting
CD44posCD24neg  tumor cells may have limited success in
preventing primary tumor metastasis unless Activin/Nodal
signaling is arrested.
Introduction
The CD24 gene encodes a highly glycosylated, glycosylphos-
phatidylinositol anchored cell surface protein [1]. Thought to
function as an adhesion molecule, it is known to bind Platelet
Activation-Dependent Granule to External Membrane Protein
(aka P-Selectin) [2] and facilitate intracellular signaling despite
lacking a transmembrane domain [3]. In both normal and can-
cerous mammary tissue, CD24 positivity is frequently associ-
ated with a terminally differentiated, luminal phenotype [4-6]. In
spite of this classification, the influence of CD24 expression
on tumorigenicity and invasiveness is inconsistent, ranging
from a positive [7-10] to a negative one [11-14].
Al-Hajj et al. [14] first described an impact of CD24 expres-
sion on breast cancer tumorigenicity by observing that
CD44posCD24neg cells were highly tumorigenic in immuno-
compromised mice while CD44posCD24pos were nontumori-
genic. Since then, the CD44/CD24 profile has been widely
investigated in both primary tissues [4,15-22] and established
breast cancer cell lines [13,23-31].
7AAD: 7-aminoactinomycin D; APC: allophycocyanin; E-cad: E-cadherin; FACS: fluorescence activated cell sorting; FBS: fetal bovine calf serum; 
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A relationship between CD24 and basal or luminal phenotype
in breast cancer cell lines was reported by Fillmore and Kup-
perwasser [11]. Specifically, these authors demonstrated that
cell lines with a high percentage of CD24pos cells expressed
luminal keratins while cell lines with a high percentage of
CD24neg cells expressed basal keratins. Consistent with these
observations, CD44highCD24neg cells were found to possess
a basal/mesenchymal phenotype relative to CD44lowCD24pos
cells [13]. Furthermore, using breast cancer cell lines,
Sheridan et al. [27] demonstrated that CD44posCD24neg cells
were more invasive than CD44posCD24pos cells. The invasive
nature of CD44posCD24neg breast cancer cells has made this
population a possible therapeutic target with the goal of elim-
inating the metastatic ability of primary tumors. Indeed, efforts
to specifically target this population have been described [29-
31].
Detailed comparisons between CD44neg/lowCD24pos  and
CD44posCD24neg  breast cancer cells have been reported
[4,13,32]. While CD44neg/lowCD24pos cells lack the ability to
give rise to their invasive CD44posCD24neg counterpart [13],
the regulation of CD24 and the invasive, CD44posCD24neg
phenotype in CD44 positive breast cancer cells is less well
understood. Our decision to work exclusively with CD44pos
cells was a deliberate effort to focus specifically on CD24 and
avoid the well-described influence of CD44 expression on cell
behavior [33-36].
Herein, we report that CD24 is under dynamic regulation in
vivo and in vitro in five breast cancer cell lines. Specifically,
CD44posCD24pos cells readily give rise to CD44posCD24neg
cells and vice versa. Furthermore, noninvasive, epithelial-like
CD44posCD24pos  cells give rise to invasive, mesenchymal
CD44posCD24neg  progeny in an Activin/Nodal dependent
manner.  In vivo, this interconversion resulted in
CD44posCD24pos cells giving rise to xenografts which had a
similar capacity for local invasion as those initiated with
CD44posCD24neg  cells. These observations have potential
clinical implications as specific targeting of CD44posCD24neg
cells will leave behind CD44posCD24pos cells capable of giv-
ing rise to invasive progeny unless Activin/Nodal signaling is
arrested.
Materials and methods
Cell culture
MCF7, ZR75.1, and MDA MB 231 cell lines were obtained
from American Type Tissue Culture Collection (Manassas, VA,
USA). MDA MB 231 and MCF7 cells were maintained in Dul-
becco's Minimum Essential Medium (DMEM, Invitrogen,
Gaithersburg, MD, USA) supplemented with 5% heat inacti-
vated fetal bovine serum (FBS, Invitrogen), 10 μg/ml bovine
insulin (Sigma, St. Louis, MO, USA), and 100 units/ml penicil-
lin-streptomycin (Invitrogen). ZR75.1 cells were maintained in
RPMI1640 (Invitrogen) supplemented with 10% heat inacti-
vated FBS and 100 units/ml penicillin-streptomycin.
MCF10Ca1a cells [37] (referred to as Ca1a, a kind gift of F.R.
Miller, Wayne State University, Detroit, MI, USA, through L.M.
Wakefield, CCR, NCI) were maintained in DMEM/F12 (Invitro-
gen) supplemented with 5% heat inactivated horse serum
(HS, Gemini BioProducts, West Sacramento, CA, USA) and
100 units/ml penicillin-streptomycin. SUM159 cells (Asterand,
Detroit, MI, USA) were maintained in Ham's F12 with 5% FBS,
5 μg/ml insulin, and 1 μg/ml hydrocortisone (Sigma). Cells
were passaged following trypsinization (0.05% trypsin-EDTA,
Invitrogen). The Activin/Nodal inhibitor SB-431542 [38,39]
(Sigma) was solubilized in dimethyl sulfoxide (DMSO, Sigma)
and supplemented to media at a final concentration of 10 μM
and a final DMSO concentration of 0.1%. Cells not receiving
SB-431542 were treated with 0.1% DMSO.
For generation of clonally derived cell lines, Ca1a cells were
double-sorted and single cells plated directly into 96-well
dishes containing conditioned DMEM/F12 media supple-
mented with 5% heat inactivated HS. Those wells containing
a single cell were identified microscopically and expanded.
Flow cytometric analysis and sorting
Anti-human CD44-allophycocyanin (APC, clone G44-26, 0.2
μg/ml final concentration) and anti-human CD24-phycoeryth-
rin (PE, clone ML5, 26.6 μg/ml final concentration) or anti-
human CD24-fluorescein (FITC, clone ML5, 26.6 μg/ml final
concentration) (unless otherwise noted, all antibodies were
purchased from BD Biosciences, Franklin Lakes, NJ, USA)
were used for both analysis and live sorting. 7-aminoactinomy-
cin D (7AAD, 1 μg/ml final concentration, BD Biosciences)
was used for live/dead cell distinction. For flow cytometric
analysis, cells were stained with a PBS solution containing
0.1% BSA and 0.1% sodium azide (Sigma) for 25 min at 4°C
followed by two washes with this same buffer. For dual stain-
ing of CD24 and vimentin (PE, clone VI-RE/1, 10 μg/ml final
concentration, Abcam, Cambridge, MA, USA) cells were
stained with CD24-FITC as described above followed by fixa-
tion (0.1% formaldehyde, 15 min) and permeabilization (0.5%
Tween 20, 10 min, Sigma). Staining was performed in a PBS
solution containing 0.1% BSA, 0.1% sodium azide, and 0.5%
Tween 20 for 25 min at 4°C followed by two washes with this
same buffer. Analysis was performed on either a BD Bio-
sciences FACSCalibur or LSR II. For dissociated xenografts,
gates were established post-compensation with lineageneg
cells (devoid of anti-mouse CD45neg [clone 30-F11, 6.7 ug/ml
final concentration] and anti-mouse H-2Kdneg [clone 15-5-5,
6.7 ug/ml final concentration] positive cells) that were not
exposed to anti-human CD44 or anti-human CD24 antibodies.
For live sorting, cells were stained in a PBS solution containing
1.0% FBS, 100 units/ml penicillin-streptomycin, and 1 μg/ml
Amphotericin B (Sigma) for 25 min at 4°C. Gates were estab-
lished with unstained cells. Cell sorting was performed on a
BD Biosciences FACSAria operating at Low Pressure (20 psi)
using a 100 μm nozzle. Cell clusters and doublets were elec-Available online http://breast-cancer-research.com/content/11/6/R82
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tronically gated out. Cells were routinely double-sorted and
post-sort analysis typically indicated purities of > 90% with
minimal cell death (< 10%). Flow cytometry data were ana-
lyzed using FlowJo v8.8.5 (TreeStar, Ashland, OR, USA).
In vivo tumorigenicity and processing of xenografts
In vivo tumorigenicity was assessed by both frequency and
latency of tumor formation in the abdominal mammary gland fat
pad of 8 wk old athymic NCr-nu/nu mice obtained from the
NCI colony (APA, Frederick, MD, USA). All animal experiments
were conducted in accord with accepted standards of
humane animal care and approved by the Animal Care and
Use Committee at the National Institutes of Health. Five days
prior to injection of cells, the bone marrow suppressant etopo-
side (VP-16) was administered intraperitoneally (ip, 30 mg/kg
body weight, Calbiochem, Gibbstown, NJ, USA); animals also
received a subcutaneous estrogen pellet (0.72 mg β-estradiol,
90-day release, Innovative Research of America, Sarasota, FL,
USA). Cells were suspended in a F12 (Invitrogen)/Matrigel
(high concentration, BD Biosciences) mixture (4:1) and
injected into the mammary fat pad in a 50 μl volume. Mice were
anesthetized by an ip injection of ketamine/xylazine (750 and
50 mg/kg body weight, respectively) in 200 μl Hank's Bal-
anced Salt Solution (Invitrogen) prior to surgically exposing
the gland for injection. Tumor size was measured weekly using
a caliper. Experiments were terminated once a xenograft
reached 1.0 cm in diameter or 75 d following injection of cells,
whichever came first. Xenografts were removed, minced into
< 1 mm pieces, and dissociated (F12 media containing 100
units/ml Collagenase type 3 (Worthington Biochemical Corp,
Lakewood, NJ, USA), 0.8 units/ml Dispase (Invitrogen), and
100 units/ml penicillin-streptomycin) at 37°C under rotating
conditions for 90 to 120 min. Single cells were generated by
an additional incubation in 0.05% trypsin-EDTA for 5 min at
37°C. Hematoxylin and eosin (H&E) stained sections of mam-
mary glands devoid of frank tumors were examined for the
presence of macroscopic lesions.
siRNA mediated knockdown of CD24
Non-targeting and CD24 siRNA pools were purchased from
Dharmacon (Lafayette, CO, USA). Ca1a cells were trans-
fected with 50 nM siRNA using DharmaFECT 1. Cells were
harvested 72 hr post-transfection.
Matrigel invasion assays
Cell invasion was assessed using Matrigel coated transwell
chambers (8 μm, BD Biosciences). For analysis of sorted
cells, cells were counted post-sorting using a Cellometer
AutoT4 (Nexcelom Bioscience, Lawrence, MA, USA). For
siRNA experiments, cells were trypsinized 24 hr post-transfec-
tion and counted. For both experiments, 30,000 cells were
plated in triplicate in media containing 0.1% HS. Media con-
taining 15% HS was used as the chemoattractant. Cells that
had invaded 48 hr later were fixed with methanol, stained with
1% toluidine blue and counted under 20× magnification.
Realtime RT-PCR
Total RNA was isolated from cells using the QIAGEN RNeasy
kit (Valencia, CA, USA). The QIAGEN AllPrep DNA/RNA kit
was used to isolate genomic DNA. RNA was reverse tran-
scribed using Moloney murine leukemia virus reverse tran-
scriptase (Invitrogen) primed with oligo-dT and random
hexamers. The cDNA was then subjected to realtime PCR
amplification using gene specific primers and 2× Brilliant II
Sybr Green QPCR Mastermix (Roche Applied Science, Indi-
anapolis, IN, USA). Primer sequences and PCR conditions are
provided (see Additional data file 1). GADPH was employed
as a housekeeping gene after confirming that it is expressed at
similar levels between the CD44posCD24pos  and
CD44posCD24neg cells (see Additional data file 2). Data are
presented as mean delta delta Ct relative to CD44posCD24pos
cells.
Immunoflouresence and confocal microscopy
Cells were either grown on ibidi 8-well chamber slides
(Research Products International, Mt. Prospect, IL, USA) and
fixed/permeabilized with ice cold acetone or sorted live, fixed/
permeabilized with ice cold acetone followed by cytospin
preparation. Following fixation, cells were blocked with 1%
BSA. Primary antibodies (anti-Slug [clone D-19, 2 μg/ml final
concentration] and anti-vimentin [clone H-84, 2 μg/ml final
concentration], Santa Cruz Biotechnology, Santa Cruz, CA)
were followed by the appropriate secondary antibody (anti-
goat or anti-rabbit Alexa Fluor 594 or Alexa Fluor 488, 1:1000
dilution, Invitrogen). Imaging was performed using the Carl
Zeiss LSM510 confocal imaging system (Carl Zeiss MicroIm-
aging, Thornwood, NY, USA) at 63× magnification or an Olym-
pus IX51 microscope (Olympus, Center Valley, PA, USA) at
20× magnification.
Bisulfite sequencing
Bisulfite modification was performed on genomic DNA iso-
lated from CD44posCD24pos or CD44posCD24neg sorted cells
using the QIAGEN EpiTect Bisulfite Kit. Primers for PCR
amplification were designed with MethPrimer [40] and a
region spanning 366 bases and 28 CpG dinucleotides start-
ing at -422 relative to the transcriptional start sight was que-
ried (forward 5' GTTTATTAAATTGTTTAATGGTAATTA 3',
reverse 5' ATCTTCCCAAAAACTAAAAAACC 3'). PCR prod-
ucts were cloned into DH5α cells by TOPO TA cloning (Invit-
rogen) and sequenced using M13 primers.
RNA stability assay
Following sorting into CD44posCD24pos  and
CD44posCD24neg populations, cells were seeded into six-well
dishes. One day later, cells were treated with 10 μg/ml Actin-
omycin-D (Sigma) and collected at 0, 4, 8, or 16 hr. RNA was
isolated using Trizol (Invitrogen). Changes in CD24 mRNA
were monitored by realtime RT-PCR.Breast Cancer Research    Vol 11 No 6    Meyer et al.
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Statistics
Analysis of variance was performed using StatView 5.0.1
(SAS Institute, Cary, NC, USA). For analysis of realtime RT-
PCR data, technical replicates for each gene from each of
three independent experiments were averaged. Analysis of
variance was performed on the resulting three independent
values.
Results
CD24 expression is dynamically regulated in breast 
cancer cell lines
In an effort to understand the dynamics of CD24 expression in
breast cancer cell lines, cells were sorted based on their
CD44 CD24 expression and the CD44/CD24 expression of
their progeny was evaluated. Nineteen breast cancer cells
lines were initially screened for their expression of CD44 and
CD24 (see Additional data file 3). Four cell lines (Ca1a,
MCF7, SUM159 and MDA MB 231) were selected to evalu-
ate the fluidity of CD24 expression in vitro. Cells were sorted
into CD44posCD24neg and CD44posCD24pos populations (see
Figure 1
CD24 expression is dynamically regulated in breast cancer cell lines CD24 expression is dynamically regulated in breast cancer cell lines. (a) CD44posCD24neg and CD44posCD24pos cells were sorted from Ca1a, 
SUM159, MCF7, or MDA MB 231 breast cancer cell lines and expanded in vitro. The CD44, CD24 expression profile of the sorted cells was 
assessed via flow cytometry after two passages. (b) CD24 promoter CpG islands as predicted by MethPrimer (top panel). A 366 bp region was 
queried by bisulfate sequencing analysis (BS1, -422 to -788 relative to transcriptional start site). Bisulfite sequencing analysis of CD24 promoter in 
CD44posCD24pos and CD44posCD24neg parental Ca1a cells. Methylated CG (filled circles) and unmethylated CG (open circles) are presented (mid-
dle panel). Percentages of methylation of each CpG in the CD24 promoter from region queried (bottom panel). (c) CD24 mRNA stability assessed 
in Actinomycin treated, sorted cells. CD44posCD24pos (blue line) and CD44posCD24neg (red line) differences are presented as delta delta Ct means 
+/- standard deviations around the mean.Available online http://breast-cancer-research.com/content/11/6/R82
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Additional data file 4) and allowed to expand for two passages
after which their CD44/CD24 expression was assessed by
flow cytometry. For all four cell lines queried, CD44posCD24neg
cells gave rise to CD44posCD24pos cells and vice versa (Fig-
ure 1a).
Data presented above suggests that CD24 expression is
dynamically regulated in immortalized breast cancer cell lines.
To evaluate if the CD24 gene was susceptible to dynamic
transcriptional regulation, CpG methylation status of the
CD24 promoter was queried in CD44posCD24neg  and
CD44posCD24pos populations sorted from the Ca1a cell line.
A region spanning 366 bases (starting at -422 relative to the
transcriptional start site) and 28 CpG dinucleotides was que-
ried via bisulfite sequencing (Figure 1b). No differences in
CpG methylation were observed between CD44posCD24neg
and CD44posCD24pos cells. This suggests that rapid changes
in CD24 transcription can occur without necessitating epige-
netic modification of its promoter.
To further understand the regulation of CD24 expression, sta-
bility of the transcript was compared between
CD44posCD24neg and CD44posCD24pos FACS sorted Ca1a
cells. Following sorting, transcription was inhibited with Actin-
omycin-D and the rate of CD24 mRNA disappearance was
evaluated. As indicated in Figure 1c, differences in CD24
abundance between CD44posCD24neg and CD44posCD24pos
cells is not achieved by altered mRNA stability. CD24 expres-
sion as evaluated by flow cytometry could also be regulated at
the translational level or by cell surface localization of the pro-
tein. However, given that cells devoid of the protein at the cell
surface have markedly depressed levels of CD24 transcript
(roughly one tenth that of CD24 positive cells) indicates that
transcriptional regulation plays a considerable role in regulat-
ing CD24 protein expression.
Noninvasive CD44posCD24pos cells give rise to invasive 
CD44posCD24neg cells
We next set out to determine whether CD44posCD24pos cells
could give rise to functional heterogeneity in addition to immu-
nophenotypic heterogeneity as demonstrated above. It had
been previously reported that CD44posCD24neg cells possess
an invasive, mesenchymal phenotype relative to the epithelial-
like phenotype of CD44dim/posCD24pos cells [13,27]. After
sorting Ca1a cells, we confirmed that relative to
CD44posCD24pos  cells, the CD44posCD24neg  population
expressed elevated levels of Slug and vimentin and reduced
levels of E-cadherin (Figure 2a, b, c). To confirm vimentin
expression, Ca1a cells were dual stained for CD24 and vimen-
tin. Consistent with data in Figure 2b, 92% of
CD44posCD24neg cells were vimentin positive and expressed
the protein at elevated levels (median fluorescence intensity =
1,494). While 32% of CD44posCD24pos cells fell in the vimen-
tin positive gate, these cells expressed the protein at markedly
lower levels (median fluorescence intensity = 7) than CD24neg
cells (see Additional data file 5). Furthermore, this population
was nearly eight-fold more invasive through Matrigel than
CD44posCD24pos cells (Figure 2d).
We took advantage of these differences between
CD44posCD24pos and CD44posCD24neg cells to evaluate if
either population possessed the ability to give rise to molecu-
lar and functional heterogeneity. Specifically, we set out to
determine if the CD44posCD24neg  progeny of noninvasive
CD44posCD24pos cells possessed an invasive, mesenchymal
phenotype. To address this question in the most stringent
manner possible, clones were propagated from
CD44posCD24neg or CD44posCD24pos Ca1a cells (Figure 3a).
Following a double sort, single cells were deposited into 96-
well dishes and expanded. Only wells confirmed to contain a
single cell after sorting (determined microscopically) were
evaluated. Less than 1.5% of CD44neg cells were able to gen-
erate clones, independent of CD24 status, indicating that
these cells lack self-renewal properties (data not shown).
Seven clones were generated from sorted CD44posCD24pos
cells and five clones were generated from CD44posCD24neg
cells with roughly 30% of single cells giving rise to a success-
ful colony, independent of CD24 expression (data not shown).
For all clones, CD44posCD24neg  cells gave rise to
CD44posCD24neg cells, and vice versa (see Additional data file
6). FACS profiles of clones derived from a CD44posCD24pos
cell or a CD44posCD24neg cell are presented in Figure 3b
demonstrating the ability of a single CD44posCD24pos cell to
give rise to isogenic CD44posCD24neg  progeny, and vice
versa. These observations confirmed data generated with bulk
sorted Ca1a, SUM159, MCF7, and MDA MB 231 cells (Fig-
ure 1a).
As presented in Figure 2, the parental Ca1a cell line pos-
sesses two functionally unique populations (invasive
CD44posCD24neg  cells and noninvasive CD44posCD24pos
cells). To determine if either CD44posCD24pos  or
CD44posCD24neg cells possessed the ability to give rise to this
molecular and functional heterogeneity, the clones described
above were sorted and queried for expression of mesen-
chyme-related genes as well as invasiveness through Matrigel.
We observed that a single noninvasive, epithelial-like
CD44posCD24pos cell had the ability to give rise to isogenic,
CD44posCD24negprogeny possessing elevated levels of Snail
and Slug and reduced levels of E-cadherin (Figure 3c). Fur-
thermore, these CD44posCD24neg progeny were 5-fold more
invasive than their CD44posCD24pos parental cell (Figure 3d).
Likewise, a single CD44posCD24neg cell had the ability to give
rise to noninvasive, epithelial-like, CD44posCD24pos progeny
(Figures 3c, d). These data demonstrate that
CD44posCD24pos cells are plastic and can readily give rise to
progeny possessing molecular and functional characteristics
unlike their own.Breast Cancer Research    Vol 11 No 6    Meyer et al.
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Xenografts derived from CD44posCD24pos cells are locally 
invasive and contain CD44posCD24neg progeny
Data presented above demonstrate that noninvasive
CD44posCD24pos  cells readily give rise to invasive
CD44posCD24neg progeny. To determine if this is limited to in
vitro conditions, three cell lines (Ca1a, MCF7 and ZR75.1)
were sorted into CD44posCD24pos and CD44posCD24neg pop-
ulations and injected into the abdominal fat pad of immuno-
compromised mice. Not surprisingly, we observed differences
among cell lines in tumorigenicity (Figure 4a, b). In all cases,
within cell lines, CD44posCD24pos and CD44posCD24neg pop-
ulations were equally tumorigenic (Figure 4a, b). In the case of
Ca1a, 10 cells from either CD44posCD24pos  or
CD44posCD24neg cells resulted in a similar frequency (Figure
4a) of equally sized tumors (P = 0.89, data not shown). Both
populations gave rise to tumors greater than 1 cm in diameter
within 50 days of injection. One thousand ZR75.1 cells, inde-
pendent of CD24 status, resulted in 100% of mice developing
tumors by 62 days post injection (Figure 4a) with
CD44posCD24neg cells yielding 1.9 fold larger tumors than
CD44posCD24pos cells (P < 0.05, data not shown). When 500
ZR75.1 cells were injected, 2/5 mice and 1/4 mice developed
tumors by 75 days when injected with CD44posCD24pos or
CD44posCD24neg cells, respectively (Figure 4b) without a dif-
ference in tumor volume (P = 0.56, data not shown). Likewise,
the injection of 10,000 MCF7 cells resulted in 100% tumor
incidence within 50 days (Figure 4a) with no difference in
tumor volume (P = 0.23, data not shown).
Figure 2
CD44posCD24neg cells possess an invasive, mesenchymal phenotype CD44posCD24neg cells possess an invasive, mesenchymal phenotype. (a) Total RNA was isolated from CD44posCD24neg and CD44posCD24pos cells 
sorted from parental Ca1a cells and transcript abundance was evaluated via realtime RT-PCR. CD44posCD24neg (red bars) and CD44posCD24pos 
(blue bars) differences are presented using the delta delta Ct method. Graphs represent means and associated standard errors of three independ-
ent experiments. * indicates P < 0.05. (b, c) Immunofluorescent staining of Slug (green) (b), vimentin (red) (c), and DAPI (blue) in cytospin prepara-
tions derived from parental Ca1a cells sorted into CD44posCD24neg and CD44posCD24pos populations. (d) Invasion through Matrigel by sorted 
parental Ca1a CD44posCD24neg (red bar) and CD44posCD24pos (blue bar) cells. Invaded cells were counted 48 hr following seeding. Graphs repre-
sent averages and associated standard errors of experiments performed in triplicate. * indicates P < 0.05.Available online http://breast-cancer-research.com/content/11/6/R82
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Figure 3
Clones generated from a single CD44posCD24pos or CD44posCD24neg cell possess molecular and functional heterogeneity similar to that of parental  line Clones generated from a single CD44posCD24pos or CD44posCD24neg cell possess molecular and functional heterogeneity similar to that of parental 
line. (a) Clones were generated by sorting single Ca1a CD44posCD24pos or CD44posCD24neg cells into individual wells of 96-well plates. Only wells 
confirmed to contain a single cell were expanded. (b) CD44/CD24 expression of representative clones derived from a single CD44posCD24neg or 
CD44posCD24pos cell. From the experiment described in (a), seven clones were generated from sorted CD44posCD24pos cells and five clones were 
generated from CD44posCD24neg cells. The CD44/CD24 profiles of representative clones are presented. (c) Total RNA was isolated from isogenic 
CD44posCD24neg and CD44posCD24pos cells sorted from the clones described in (a, b) and transcript abundance was evaluated via realtime RT-
PCR. Data generated with cells sorted from a clone derived from a single CD44posCD24neg cell are presented in red. Data generated with cells 
sorted from a clone derived from a single CD44posCD24pos cell are presented in blue. CD44posCD24neg (closed bars) and CD44posCD24pos (open 
bars) differences are presented using the delta delta Ct method. Graphs represent means and associated standard errors of three independent 
experiments. * indicates P < 0.05. (d) Invasion through Matrigel by isogenic CD44posCD24neg and CD44posCD24poscells freshly sorted from the 
clones described in (a, b, c). 48 hr following seeding, invaded cells were counted. Graphs represent averages and associated standard errors of 
experiments performed in triplicate. Data generated with cells sorted from a clone derived from a single CD44posCD24neg cell are presented in red. 
Data generated with cells sorted from clone derived from a single CD44posCD24pos cell are presented in blue. * indicates P < 0.05.Breast Cancer Research    Vol 11 No 6    Meyer et al.
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Once xenografts reached 1 cm in diameter they were
removed, dissociated, and subjected to flow cytometric analy-
sis. Contaminating host cells were excluded by gating out H-
2Kd pos and mouse specific CD45pos cells. While the CD44/
CD24 profile of resulting xenografts is not identical to that of
the parental cell line, CD44posCD24pos cells readily gave rise
to CD44posCD24neg progeny in vivo, and vice versa (Figure
4c). This latter observation is consistent with our in vitro obser-
vations. More importantly, we observed that xenografts initi-
ated with either CD44posCD24pos or CD44posCD24neg cells
had a capacity for local invasion (Figure 4d). These observa-
tions confirmed that progeny of noninvasive CD44posCD24pos
cells yield progeny capable of invading surrounding tissues.
Requirement for Activin/Nodal signaling in the 
generation of molecular heterogeneity
The role Activin/Nodal signaling plays in the generation of
molecular and functional heterogeneity by CD44posCD24pos
and CD44posCD24neg cells was explored with the use of SB-
431542, a small molecule inhibitor of ALK4, -5, -7 [38,39].
Immediately post-sorting, vimentin expression was greatest in
CD44posCD24neg cells and low/negative in CD44posCD24pos
subpopulations (Figures 2c, 5). As expected, 96 hours post-
sorting, vehicle treated CD44posCD24pos  cells and
CD44posCD24neg cells gave rise to progeny with molecular
heterogeneity (Figure 5). Specifically, epithelial-like, vimentin
negative/low CD44posCD24pos cells gave rise to mixed prog-
Figure 4
Xenografts derived from CD44posCD24pos cells are locally invasive and contain CD44posCD24neg progeny Xenografts derived from CD44posCD24pos cells are locally invasive and contain CD44posCD24neg progeny. (a) Ca1a (top), ZR75.1 (middle), and 
MCF7 (bottom) breast cancer cells were FACS sorted based on their CD44, CD24 expression and injected into the abdominal mammary fat pad of 
nu/nu mice in 50 μl of a 25% Matrigel suspension. Latency of tumor formation following orthotopic injection of sorted CD44posCD24neg/dim (red line) 
or CD44posCD24pos (blue line) breast cancer cells is presented. Five mice per population were injected and palpated weekly. (b) Limiting dilution of 
tumor initiating cells in sorted ZR75.1 and Ca1a cells. (c) Xenografts established with either CD44posCD24neg or CD44posCD24pos cells were disso-
ciated and evaluated for CD44/C24 expression. Host cells were excluded with mouse anti-CD45, and -H-2Kd antibodies as described in the Meth-
ods section. Representative FACS profiles of xenografts initiated with sorted Ca1a, ZR75.1, and MCF7 cells are presented. (d) Local invasion of 
xenografts established by injecting CD44posCD24neg or CD44posCD24pos sorted Ca1a or ZR75.1 cells into the abdominal mammary fat pad of nude 
mice. Representative H&E stained sections of the resulting xenografts are presented. Black arrows indicate host tissue. Light blue arrows indicate 
invading tumor cells.Available online http://breast-cancer-research.com/content/11/6/R82
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eny; some expressed high levels of vimentin and others lacked
the mesenchymal marker. Similarly, mesenchymal, vimentin
positive CD44posCD24neg cells expanded giving rise to a
mixed population of vimentin negative and positive progeny.
Following treatment with SB-431542, however, vimentin low/
negative CD44posCD24pos cells gave rise to uniformly vimentin
negative progeny. CD44posCD24neg cells treated with SB-
431542 gave rise to homogeneously vimentin positive prog-
eny (Figure 5). These data demonstrate that active Activin/
Nodal signaling is not required for expansion of either
CD44posCD24pos or CD44posCD24neg cells. However, both
populations require this pathway in order to give rise to molec-
ular heterogeneity. Specifically, Activin/Nodal signaling is
required for vimentin positive, CD44posCD24neg cells to give
rise to vimentin negative progeny and for vimentin negative,
CD44posCD24pos cells to give rise to vimentin positive prog-
eny.
Depletion of CD24 caused increased invasiveness 
without yielding a mesenchymal phenotype
We next sought to evaluate whether the lack of CD24 expres-
sion is upstream or downstream of the mesenchymal pheno-
type associated with CD24 negativity. Seventy two hours
following transient transfection using a pool of siRNA targeting
CD24 yielded a seven-fold increase in the percentage of
CD24neg cells and a concomitant 26-fold decrease in median
fluorescence intensity relative to cells transfected with non-tar-
geting siRNA (Figure 6a). Depletion of CD24 expression did
not yield a mesenchymal phenotype based on the expression
of E-cadherin, Snail, Slug, and Twist (Figure 6b) but instead
resulted in a reduction in Slug mRNA (P < 0.05). Consistent
with an apparent lack of epithelial to mesenchymal transition,
CD24 siRNA similarly failed to alter cell morphology (data not
shown). Despite this lack of mesenchymal phenotype, CD24
siRNA transfected cells were 3.5-fold more invasive than non-
targeting siRNA transfected cells (Figure 6c). In the invasion
experiments, cells were counted and seeded to invasion
chambers 24 h post transfection. The number of invading cells
was counted 72 h post transfection. These data indicate that
exogenous down regulation of CD24 is sufficient to yield
increased invasiveness. However, it is unable to elicit a mes-
enchymal phenotype associated with endogenous down reg-
ulation of CD24.
Discussion
Herein, we demonstrate that noninvasive, epithelial-like
CD44posCD24pos cells readily give rise to invasive, mesenchy-
mal CD44posCD24neg  progeny. This plasticity, which is
dependent upon Activin/Nodal signaling, is the likely mecha-
nism by which noninvasive, epithelial-like CD44posCD24pos
cells give rise to xenografts with locally invasive boundaries.
Cell motility is a fundamental aspect to early cancer metasta-
sis. The ability of single cells to move from the primary tumor is
Figure 5
Role of Activin/Nodal signaling in the generation of molecular heterogeneity Role of Activin/Nodal signaling in the generation of molecular heterogeneity. Ca1a cells were sorted into CD44posCD24neg and CD44posCD24pos 
populations. Cytospin prepared cells were stained for vimentin immediately following sorting (left two panels, bar represents 200 μm). Sorted cells 
were allowed to expand for 96 hr in the presence of vehicle (0.1% DMSO, middle two panels) or 10 μM SB-431542 (right two panels). Immunoflu-
orescent staining of vimentin (green) and DAPI (blue) is presented. In the absence of drug, CD44posCD24poscells yield mesenchymal, vimentin pos-
itive progeny. Inhibition of Activin/Nodal signaling prevents this interconverstion.Breast Cancer Research    Vol 11 No 6    Meyer et al.
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frequently facilitated via the transition from an epithelial to a
mesenchymal phenotype. Indeed, tumors that possess a mes-
enchymal gene signature correlate with tumor progression
and poor prognosis [41-43]. As such, direct targeting of the
invasive, mesenchymal component of primary breast cancer
could be of substantial clinical benefit. The acquisition of a
mesenchymal phenotype is associated with, among other
things, the loss of E-cadherin [44] and increased vimentin
expression [45]. Recently, CD44posCD24neg breast cancer
cells were demonstrated to possess this mesenchymal pheno-
type [13] and we herein extended these observations. The
specific targeting of CD44posCD24neg cells has proven effec-
tive at reducing the frequency of this population [29-31]. Our
interest was in broadening the understanding of regulation of
the CD24 gene and the invasive, mesenchymal
CD44posCD24neg population in breast cancer cell lines.
Molecular and functional differences between CD44neg/
dimCD24pos and CD44posCD24neg cells have been eloquently
described, including the observation that the former cannot
give rise to the latter [4,13,32]. However, CD44 expression is
known to profoundly impact cell behavior. Relative to CD44pos
cancer cells, those with low to no CD44 expression have
reduced growth, invasiveness, and tumorigenicity, heightened
susceptibility to chemotherapeutics, and reduced levels of
pluripotent stem cell markers [33,34,46-48]. Indeed, we
observed that fewer than 2% of CD44dim/neg cells (independ-
ent of CD24 status) gave rise to colonies in vitro. Due to the
well-characterized dominant effect of CD44 on cell behavior
and the fact that previous work has compared CD44dim/neg to
CD44pos cells [4,13,32], the regulation of CD24 and its spe-
cific role in breast cancer cell behavior is largely unknown.
We demonstrated in vitro and in vivo that CD24 expression is
dynamically regulated. Specifically, CD44posCD24pos  cells
readily gave rise to CD44posCD24neg progeny and vice versa.
This was stringently confirmed in vitro by demonstrating that
clones derived from a single CD44posCD24pos cell yielded
CD44posCD24neg progeny. In non-transformed mammary epi-
thelial cells, CD24 positivity is frequently associated with a ter-
minally differentiated, luminal phenotype [5,6,49]. Such
lineage commitment and long-term modification of gene
expression is frequently achieved via alterations in promoter
CpG dinucleotide methylation [50,51]. In our study, bisulfite
sequencing analysis revealed that CD24 promoter methylation
is similar between CD44posCD24neg and CD44posCD24pos
cells suggesting that transcription can be rapidly altered with-
out requiring changes in promoter methylation. Data pre-
sented herein do not rule out regulation of CD24 expression
by modified translation or cell surface localization of the pro-
tein. However, these findings are consistent with our data
demonstrating that the gene is indeed susceptible to dynamic
transcriptional regulation. Furthermore, others have shown in
MCF10A, a normal mammary cell line, that CD24 expression
is under the regulatory control of Wnt signaling [52].
More importantly, the clones we generated confirmed that
CD44posCD24pos cells give rise to functionally heterogeneous
progeny. Specifically, we demonstrated that a single noninva-
sive, epithelial-like CD44posCD24pos cell could give rise to
Figure 6
Depletion of CD24 caused increased invasiveness without yielding a mesenchymal phenotype Depletion of CD24 caused increased invasiveness without yielding a mesenchymal phenotype. (a) Ca1a cells were transfected with non-targeting or 
CD24 siRNA. Histogram illustrates CD24-PE fluorescence intensity of unstained cells (black line) and cells transfected with CD24 siRNA (red line) 
or non-targeting siRNA (blue line) as assessed by flow cytometric analysis. (b) Total RNA was isolated from cells following transfection with non-tar-
geting or CD24-targeting siRNA. Transcript abundance was evaluated via realtime RT-PCR. Non-targeting siRNA transfected cell (blue bars) and 
CD24-targeting siRNA transfected cell (red bars) differences are presented using the delta delta Ct method. Graphs represent means and associ-
ated standard errors of experiments performed in triplicate. * indicates P < 0.05. (c), 24 hr following transfection with either non-targeting or CD24 
siRNA, Ca1a cells were trypsinized, counted, and seeded to Matrigel invasion chambers in triplicate. Invaded cells were counted 48 hr later. Graph 
represents mean fold change in invaded cells associated with CD24 siRNA transfection and associated standard errors. * indicates P < 0.05.Available online http://breast-cancer-research.com/content/11/6/R82
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CD44posCD24neg  progeny with an invasive, mesenchymal
phenotype. Similarly, xenografts initiated with
CD44posCD24pos cells contained CD44posCD24neg progeny.
Furthermore, these xenografts were as invasive as those initi-
ated with CD44posCD24neg cells. These observations demon-
strate that while CD44posCD24pos cells are noninvasive, they
are fully capable of giving rise to invasive progeny.
Recently, Chang et al. [53] described a similar phenomenon in
clones derived from Sca-1high and Sca-1low multipotent mouse
hematopoietic cells. They reported that isogenic Sca-1high and
Sca-1low cells, despite both being multipotent, had divergent
global gene expression profiles and were functionally different.
Furthermore, Sca-1high cells gave rise to Sca-1 low cells and
vice versa. Our findings, and those of Chang et al. [53], dem-
onstrate the fundamental plasticity in functional heterogeneity
present in isogenic mammalian cells.
Efforts are currently underway to specifically target
CD44posCD24neg breast cancer cells due to their invasive,
mesenchymal phenotype [29-31] and hypothesized role in
seeding distant metastases. The data described herein have
potential clinical implications as specific targeting of
CD44posCD24neg  cells will leave behind CD44posCD24pos
cells that we demonstrate are capable of giving rise to invasive
progeny. In an effort to address this, we sought to identify key
pathways required by CD44posCD24pos cells to give rise to
mesenchymal progeny. Relative to CD44negCD24pos breast
cancer cells, Shipitsin et al. [4] found the TGFβ pathway was
active in CD44posCD24neg cells. CD44 expression has been
demonstrated to regulate TGFβ signaling [35,54], so we
chose to evaluate the influence of CD24 expression on
Activin/Nodal signaling and vice versa in CD44pos cells. To do
so, we treated CD44posCD24neg and CD44posCD24pos cells
with the Activin/Nodal inhibitor, SB-431542 [38,39]. These
experiments demonstrated that Activin/Nodal signaling was
not required for the expansion of either population, i.e. vimentin
negative CD44posCD24pos  cells expanded giving rise to
vimentin negative progeny in the presence of the drug. Like-
wise, SB-431542 treated vimentin positive CD44posCD24neg
cells gave rise to vimentin positive progeny. However, we dem-
onstrated that both CD44posCD24pos and CD44posCD24neg
cells require Activin/Nodal signaling in the generation of phe-
notypically diverse progeny. Most substantially, SB-431542
exposure to epithelial-like CD44posCD24pos cells blocked their
ability to give rise to mesenchymal, vimentin positive progeny.
These findings also demonstrate that despite the molecular
and functional differences between CD44posCD24pos  and
CD44posCD24neg  cells, both populations share a similar
requirement for Activin/Nodal signaling in the generation of
functionally heterogeneous progeny, thus making this pathway
an exciting candidate to target clinically.
When CD24 expression was depleted exogenously, cell inva-
siveness increased. However, this invasiveness was not asso-
ciated with changes in gene expression seen when CD24
expression is reduced endogenously. Increased invasiveness
in the absence of elevated Snail or Slug expression has been
previously reported in the literature. Specifically, β-catenin-
lymphoid enhancer factor-1 expression yields increased inva-
siveness in colon carcinoma without increasing Snail or Slug
expression [55]. Our observations suggest that the endog-
enous down regulation of CD24 is likely not an upstream event
in the acquisition of the invasive, mesenchymal phenotype by
CD44posCD24neg progeny of CD44posCD24pos cells. How-
ever, the current experiments were not able to determine if
exogenous depletion of CD24 yielded a phenotype with simi-
lar levels of invasiveness as cells devoid of CD24 via endog-
enous means. A diagram outlining the proposed role of
Activin/Nodal signaling in the regulation of CD24 and the inva-
sive CD44posCD24neg phenotype is provided in Figure 7.
Conclusions
Herein we report that while CD44posCD24pos breast cancer
cells represent a noninvasive, epithelial phenotype, they give
rise to xenografts with a profound capacity for local invasion.
This ability to form invasive tumors was ascribed to the fact
that CD44posCD24pos  cells readily give rise to
CD44posCD24neg cells that possess an invasive, mesenchy-
mal phenotype. The plasticity of CD44posCD24pos cells was
blocked with SB-431542 indicating that ablation of Activin/
Nodal signaling may be required in combination with therapies
targeting CD44posCD24neg cells when breast cancer cell lines
are used as models.
Figure 7
Dynamic regulation of CD24 and the invasive CD44posCD24neg pheno- type Dynamic regulation of CD24 and the invasive CD44posCD24neg pheno-
type. Schematic representation of the plasticity of the 
CD44posCD24neg, invasive/mesenchymal phenotype. Inhibition of 
Activin/Nodal signaling blocks the ability of CD44posCD24pos cells to 
give rise to invasive, mesenchymal progeny and CD44posCD24neg cells 
are prevented from giving rise to non-invasive, epithelial progeny. 
Depletion of CD24 via siRNA causes increased invasiveness without 
yielding a mesenchymal phenotype.Breast Cancer Research    Vol 11 No 6    Meyer et al.
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